Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 2/20 | 0.48 |
| ▸ | PAK3 | O75914 | 1/20 | 0.48 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 10/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065076 | 0.90 | PAK1 (0.50) | PAK1PAK3PAK2IGF1RPAK4 | |
| SCHEMBL24065149 | 0.84 | IGF1R (0.44) | PAK1PAK3PAK2IGF1RPAK4 | |
| SCHEMBL24065075 | 0.83 | PAK1 (0.56) | PAK1PAK3PAK2IGF1RPAK4 | |
| SCHEMBL24065109 | 0.81 | IGF1R (0.42) | PAK1PAK3PAK2IGF1RPAK4 | |
| SCHEMBL24065120 | 0.80 | IGF1R (0.40) | PAK1PAK3PAK2IGF1RPAK4 | |
| SCHEMBL24065028 | 0.78 | PAK4 (0.60) | PAK1IGF1RPAK4SRCABL1 | |
| SCHEMBL24065099 | 0.78 | PAK4 (0.60) | PAK1IGF1RPAK4SRCABL1 | |
| SCHEMBL25241183 | 0.77 | IGF1R (0.43) | IGF1R | |
| SCHEMBL29592932 | 0.77 | IGF1R (0.43) | IGF1R | |
| SCHEMBL26050488 | 0.77 | IGF1R (0.54) | PAK1PAK3PAK2IGF1RPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | PAK1 222/4885PAK3 447/4885PAK2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.